CannaSoul Analytics
CannaSoul Analytics is Israel’s leading cannabis analytical laboratory. A leader in medicinal cannabis R&D, CannaSoul provides scientific data that meets global standards for developing effective, safe, and reliable cannabis-based products, treatments, and pharmaceuticals.
This CRO's proprietary profiling methods enable comprehensive analysis of over 100 cannabinoids and 100 terpenes and flavonoids, per cannabis strain, offering the broadest available coverage.
CannaSoul supports leading cannabis companies in their R&D activities, pre-clinical and clinical trials, including pharmacokinetic studies (PK) and other bioanalytics. They have expertise in regulation, clinical trial planning and execution.
CannaSoul Analytics supports clinical research on the ECS and cannabinoid metabolites via quantitative analysis of biofluids. The CannaSoul lab processes microsamples for both human and animal studies, which reduces animal usage and improves data consistency.
Offering broad coverage of unique cannabinoid identification and analysis methods paired with remote specimen collection, including:
- Support for R&D activities, pre-clinical and clinical trials, including pharmacokinetics & pharmacodynamics (PK) studies on cannabinoid effects on the ECS and metabolites
-
Full profile analytics on bioactive cannabinoids and compounds, including analytics of strains, as well as bioanalytical (PK) evidence on phytocannabinoids (CBG, CBD, THC, CBGA, CBDA, THCA)
- 2-3 THC metabolites and 3 CBD metabolites
- Over 10 endocannabinoids (Anandamide and 2-AG)
CannaSoul Analytics is GCLP approved, accredited under ISO/IEC 17025, and operates under the supervision of the Israel Health Ministry’s Cannabis Unit (Yakar).
CannaSoul Analytics is headquartered in Israel, but its highly experienced team of expert scientists provides lab services globally.